Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 26;9(3):7029.
doi: 10.4081/hr.2017.7028.

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia

Michele Gottardi  1 , Federico Mosna  1 , Sergio de Angeli  2 , Cristina Papayannidis  3 , Anna Candoni  4 , Marino Clavio  5 , Cristina Tecchio  6 , Andrea Piccin  7 , Marta Campo dell'Orto  8 , Fabio Benedetti  6 , Giovanni Martinelli  3 , Filippo Gherlinzoni  1
Affiliations

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia

Michele Gottardi et al. Hematol Rep. .
No abstract available

Keywords: Core binding factor; acute myeloid leukemia; autologous stem cell transplantation; gemtuzumab ozogamicin; immunotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival by treatment with Gemtuzumab Ozogamicin (GO). Patients receiving FLAI-GO induction therapy showed a consistent, yet nonstatistical, trend towards better Overall Survival (OS), Disease-Free Survival (DFS) and, most importantly in determining the effect of first line treatment, Event-Free Survival (EFS), as compared to a group of patients treated with FLAI. Numbers of the two groups are showed as n; only patients achieving complete remission after induction therapy were considered in determining DFS. Inclusion criteria and treatment schedule was the same in the two groups apart from the addition of GO at 3 mg/m to induction therapy at day 6 of the FLAIGO regimen.
Figure 2.
Figure 2.
Disappearance of AML1-ETO molecular transcript following in vitro purging of PBSC with Gemtuzumab Ozogamicin. Samples from PBSC collected from 5 patients affected by CBF AML at the end of consolidation were cultured in the presence or absence of Gemtuzumab Ozogamicin at a concentration of 5 μg/mL for two hours. In one patient (i.e. TG) affected by t(8;21) AML with persistent AML1-ETO transcript at the end of consolidation and in the PBSC, incubation with GO obtained the disappearance of cells expressing AML1-ETO, as tested by either direct and nested PCR. Abelson (ABL) amplification was used as internal control. TG: initials of the patient’s name; Ctrl- /Ctrl+: negative and positive controls.
See this image and copyright information in PMC

References

    1. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 2008; 35:410-7. - PubMed
    1. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor acute myelogenous leukemia with fludarabine, cytarabine and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008;113:3181-5. - PMC - PubMed
    1. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamic in: results of the MRC AML 15 trial. J Clin Oncol 2011;29:369-77. - PubMed
    1. Candoni A, Martinelli G, Toffoletti E, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008;32:1800-8. - PubMed
    1. Rowe JM, Lowenberg B. Gemtuzumab Ozogamycin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013;121:4838-41. - PubMed

LinkOut - more resources